Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec;23(4):621-636.
doi: 10.1007/s42000-024-00588-1. Epub 2024 Aug 7.

Current and experimental pharmacotherapy for the management of non-alcoholic fatty liver disease

Angeliki Katsarou  1   2 , Georgios Tsioulos  3 , Eva Kassi  4 , Antonios Chatzigeorgiou  5
Affiliations
Review

Current and experimental pharmacotherapy for the management of non-alcoholic fatty liver disease

Angeliki Katsarou et al. Hormones (Athens). 2024 Dec.

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease, with its incidence increasing in parallel with the global prevalence of obesity and type 2 diabetes mellitus. Despite our steadily increasing knowledge of its pathogenesis, there is as yet no available pharmacotherapy specifically tailored for NAFLD. To define the appropriate management, it is important to clarify the context in which the disease appears. In the case of concurrent metabolic comorbidities, NAFLD patients are treated by targeting these comorbidities, such as diabetes and obesity. Thus, GLP-1 analogs, PPAR, and SGLT2 inhibitors have recently become central to the treatment of NAFLD. In parallel, randomized trials are being conducted to explore new agents targeting known pathways involved in NAFLD progression. However, there is an imperative need to intensify the effort to design new, safe drugs with biopsy-proven efficacy. Of note, the main target of the pharmacotherapy should be directed to the regression of fibrotic NASH, as this histologic stage has been correlated with increased overall as well as liver-related morbidity and mortality. Herein we discuss the drugs currently at the forefront of NAFLD treatment.

Keywords: Drugs; Fibrosis; MASLD; NAFLD; Treatment.

PubMed Disclaimer

References

    1. Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE et al (2022) The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 7(9):851–861. https://doi.org/10.1016/S2468-1253(22)00165-0 - DOI - PubMed
    1. Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L (2023) The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 77(4):1335–1347. https://doi.org/10.1097/HEP.0000000000000004 - DOI - PubMed
    1. Younossi ZM, Henry L, Bush H, Mishra A (2018) Clinical and economic burden of nonalcoholic fatty liver disease and Nonalcoholic Steatohepatitis. Clin Liver Dis 22(1):1–10. https://doi.org/10.1016/j.cld.2017.08.001 - DOI - PubMed
    1. Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F et al (2023) A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol S016882782300418X. https://doi.org/10.1016/j.jhep.2023.06.003 - DOI
    1. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D et al (2023) AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 77(5):1797–1835. https://doi.org/10.1097/HEP.0000000000000323 - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources